← Back to Clinical Trials
Recruiting NCT06405750

NCT06405750 Left Atrial Appendage Arrhythmogenic and Thrombogenic Substrate

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06405750
Status Recruiting
Phase
Sponsor University Hospital Bispebjerg and Frederiksberg
Condition Atrial Fibrillation
Study Type INTERVENTIONAL
Enrollment 1,000 participants
Start Date 2024-08-01
Primary Completion 2035-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
left atrial appendage closure

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 1,000 participants in total. It began in 2024-08-01 with a primary completion date of 2035-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of the project is to elucidate whether it is possible to identify which patients are at risk of forming blood clots that can cause stroke based on analysis of the electrocardiogram. In connection with the operation, the small pouch known as the auricle of the heart is closed, which can be completely removed after closing. This procedure is common in patients with atrial fibrillation to protect the brain from stroke. In the project, all patients will have this auricle closed if they agree to participate in the project. After closure, the auricle is usually discarded. We will analyze the blood and the auricle tissue taken (if available) in connection with the operation itself, together with the analysis of the electrocardiogram recorded before the planned heart operation.

Eligibility Criteria

Inclusion Criteria: * signed informed consent AND * planned any open-heart surgery: * CABG * valve repair or replacement * aorta surgery * any combination of the above Exclusion Criteria: * current endocarditis * follow-up not possible

Contact & Investigator

Central Contact

Helena DOMINGUEZ, MD, PhD

✉ mdom0002@regionh.dk

📞 4522989343

Principal Investigator

Helena Dominguez

STUDY DIRECTOR

University Hospital Bispebjerg and Frederiksberg

Frequently Asked Questions

Who can join the NCT06405750 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06405750 currently recruiting?

Yes, NCT06405750 is actively recruiting participants. Contact the research team at mdom0002@regionh.dk for enrollment information.

Where is the NCT06405750 trial being conducted?

This trial is being conducted at Copenhagen, Denmark.

Who is sponsoring the NCT06405750 clinical trial?

NCT06405750 is sponsored by University Hospital Bispebjerg and Frederiksberg. The principal investigator is Helena Dominguez at University Hospital Bispebjerg and Frederiksberg. The trial plans to enroll 1,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology